The multiple myeloma market size has grown strongly in recent years. It will grow from $28.05 billion in 2025 to $30.25 billion in 2026 at a compound annual growth rate (CAGR) of 7.9%. The growth in the historic period can be attributed to increased prevalence of hematologic cancers, early adoption of chemotherapy agents, rise in diagnostic imaging usage, expansion of hospital-based treatment facilities, development of first-generation immunomodulatory drugs.
The multiple myeloma market size is expected to see strong growth in the next few years. It will grow to $41.39 billion in 2030 at a compound annual growth rate (CAGR) of 8.2%. The growth in the forecast period can be attributed to advancements in targeted therapies, rising demand for stem cell transplants, growth in precision medicine applications, increasing clinical trials pipeline, expanding use of monoclonal antibody therapies. Major trends in the forecast period include increasing development of novel immunotherapies, growing use of monoclonal antibodies in treatment regimens, rising adoption of minimally invasive diagnostic techniques, expansion of stem cell transplantation procedures, increased focus on combination therapies for improved outcomes.
The increasing prevalence of multiple myeloma is expected to drive the growth of the multiple myeloma market. Multiple myeloma is a cancer of plasma cells, a type of white blood cell, and its rising incidence is influenced by factors such as age, genetics, obesity, radiation exposure, and other medical conditions. Treatments for multiple myeloma help slow disease progression and alleviate symptoms. For instance, in February 2025, according to the American Cancer Society, a US-based voluntary health organization, the United States is projected to see around 36,110 new multiple myeloma cases and approximately 12,030 related deaths, affecting both men and women. Therefore, the increasing prevalence of multiple myeloma is propelling the market growth.
Major companies in the multiple myeloma market are focusing on novel therapies, such as CAR T-cell therapy, to gain a competitive edge. CAR T-cell therapy (Chimeric Antigen Receptor T-cell therapy) involves genetically engineering a patient’s T cells to express a chimeric antigen receptor that targets specific cancer cells. For instance, in December 2023, Bristol Myers Squibb, a US-based biopharmaceutical company, received approval for Abecma, the first CAR T-cell therapy for earlier use in patients with relapsed or refractory multiple myeloma (RRMM) who have undergone at least two prior therapies. Abecma is a B-cell maturation antigen (BCMA)-directed CAR T-cell immunotherapy. Approval was based on interim results from the KarMMa-3 Phase 3 study, which showed significant improvements in median progression-free survival (mPFS) and overall response rate (ORR).
In February 2024, AstraZeneca Plc, a UK-based pharmaceutical company, acquired Gracell Biotechnologies Inc. for an undisclosed amount. This acquisition enhances AstraZeneca’s capabilities in immuno-oncology and cellular therapies by leveraging Gracell’s FasTCAR-T GC012F platform for multiple myeloma. Gracell Biotechnologies Inc., based in China, focuses on clinical development of advanced CAR T-cell therapies for multiple myeloma.
Major companies operating in the multiple myeloma market are Pfizer Inc., Johnson & Johnson Private Limited, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Janssen Global Services LLC, Celgene Corporation, Biogen Inc., Cipla Inc., Sun Pharmaceutical Industries Ltd., Karyopharm Therapeutics Inc., Regeneron Pharmaceuticals Inc., Gilead Sciences Inc., Xencor Inc., Oncopeptides AB, BeiGene Ltd., TG Therapeutics Inc.
North America was the largest region in the multiple myeloma market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the multiple myeloma market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the multiple myeloma market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs in the multiple myeloma market have contributed to higher costs for imported diagnostic equipment, monoclonal antibodies, and advanced therapeutic agents, impacting affordability and availability across regions with heavy import dependence. These tariffs particularly affect hospital pharmacies and specialty oncology centers that rely on biologics and precision diagnostic tools. However, tariffs have also encouraged domestic biopharmaceutical manufacturing and investment, promoting long-term resilience and localized production capabilities within the oncology therapeutics supply chain.
The multiple myeloma market research report is one of a series of new reports that provides multiple myeloma market statistics, including multiple myeloma industry global market size, regional shares, competitors with a multiple myeloma market share, detailed multiple myeloma market segments, market trends and opportunities, and any further data you may need to thrive in the multiple myeloma industry. This multiple myeloma market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Multiple myeloma is a type of cancer that affects plasma cells, a kind of white blood cell. In this condition, cancerous plasma cells accumulate in the bone marrow, displacing healthy blood cells. These malignant cells produce abnormal proteins that can cause complications instead of functioning as normal antibodies.
The main treatments for multiple myeloma include medications, radiation therapy, stem cell transplant, and others. Medications are dosage forms containing one or more active compounds along with potential inert substances. Diagnosis and monitoring involve blood tests, bone marrow biopsies, urine tests, and imaging studies for both active and smoldering multiple myeloma. Treatments are distributed through hospital pharmacies, retail pharmacies, online pharmacies, and other channels.
The multiple myeloma market consists of revenues earned by entities by providing services such as treatment planning, supportive care, and diagnostic testing such as computerized tomography (CT scans), magnetic resonance imaging (MRI), and positron emission tomography (PET) scans. The market value includes the value of related goods sold by the service provider or included within the service offering. The multiple myeloma market also includes sales of thalidomide, bortezomib, and daratumumab which are used in providing multiple myeloma services. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The multiple myeloma market size is expected to see strong growth in the next few years. It will grow to $41.39 billion in 2030 at a compound annual growth rate (CAGR) of 8.2%. The growth in the forecast period can be attributed to advancements in targeted therapies, rising demand for stem cell transplants, growth in precision medicine applications, increasing clinical trials pipeline, expanding use of monoclonal antibody therapies. Major trends in the forecast period include increasing development of novel immunotherapies, growing use of monoclonal antibodies in treatment regimens, rising adoption of minimally invasive diagnostic techniques, expansion of stem cell transplantation procedures, increased focus on combination therapies for improved outcomes.
The increasing prevalence of multiple myeloma is expected to drive the growth of the multiple myeloma market. Multiple myeloma is a cancer of plasma cells, a type of white blood cell, and its rising incidence is influenced by factors such as age, genetics, obesity, radiation exposure, and other medical conditions. Treatments for multiple myeloma help slow disease progression and alleviate symptoms. For instance, in February 2025, according to the American Cancer Society, a US-based voluntary health organization, the United States is projected to see around 36,110 new multiple myeloma cases and approximately 12,030 related deaths, affecting both men and women. Therefore, the increasing prevalence of multiple myeloma is propelling the market growth.
Major companies in the multiple myeloma market are focusing on novel therapies, such as CAR T-cell therapy, to gain a competitive edge. CAR T-cell therapy (Chimeric Antigen Receptor T-cell therapy) involves genetically engineering a patient’s T cells to express a chimeric antigen receptor that targets specific cancer cells. For instance, in December 2023, Bristol Myers Squibb, a US-based biopharmaceutical company, received approval for Abecma, the first CAR T-cell therapy for earlier use in patients with relapsed or refractory multiple myeloma (RRMM) who have undergone at least two prior therapies. Abecma is a B-cell maturation antigen (BCMA)-directed CAR T-cell immunotherapy. Approval was based on interim results from the KarMMa-3 Phase 3 study, which showed significant improvements in median progression-free survival (mPFS) and overall response rate (ORR).
In February 2024, AstraZeneca Plc, a UK-based pharmaceutical company, acquired Gracell Biotechnologies Inc. for an undisclosed amount. This acquisition enhances AstraZeneca’s capabilities in immuno-oncology and cellular therapies by leveraging Gracell’s FasTCAR-T GC012F platform for multiple myeloma. Gracell Biotechnologies Inc., based in China, focuses on clinical development of advanced CAR T-cell therapies for multiple myeloma.
Major companies operating in the multiple myeloma market are Pfizer Inc., Johnson & Johnson Private Limited, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Janssen Global Services LLC, Celgene Corporation, Biogen Inc., Cipla Inc., Sun Pharmaceutical Industries Ltd., Karyopharm Therapeutics Inc., Regeneron Pharmaceuticals Inc., Gilead Sciences Inc., Xencor Inc., Oncopeptides AB, BeiGene Ltd., TG Therapeutics Inc.
North America was the largest region in the multiple myeloma market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the multiple myeloma market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the multiple myeloma market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs in the multiple myeloma market have contributed to higher costs for imported diagnostic equipment, monoclonal antibodies, and advanced therapeutic agents, impacting affordability and availability across regions with heavy import dependence. These tariffs particularly affect hospital pharmacies and specialty oncology centers that rely on biologics and precision diagnostic tools. However, tariffs have also encouraged domestic biopharmaceutical manufacturing and investment, promoting long-term resilience and localized production capabilities within the oncology therapeutics supply chain.
The multiple myeloma market research report is one of a series of new reports that provides multiple myeloma market statistics, including multiple myeloma industry global market size, regional shares, competitors with a multiple myeloma market share, detailed multiple myeloma market segments, market trends and opportunities, and any further data you may need to thrive in the multiple myeloma industry. This multiple myeloma market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Multiple myeloma is a type of cancer that affects plasma cells, a kind of white blood cell. In this condition, cancerous plasma cells accumulate in the bone marrow, displacing healthy blood cells. These malignant cells produce abnormal proteins that can cause complications instead of functioning as normal antibodies.
The main treatments for multiple myeloma include medications, radiation therapy, stem cell transplant, and others. Medications are dosage forms containing one or more active compounds along with potential inert substances. Diagnosis and monitoring involve blood tests, bone marrow biopsies, urine tests, and imaging studies for both active and smoldering multiple myeloma. Treatments are distributed through hospital pharmacies, retail pharmacies, online pharmacies, and other channels.
The multiple myeloma market consists of revenues earned by entities by providing services such as treatment planning, supportive care, and diagnostic testing such as computerized tomography (CT scans), magnetic resonance imaging (MRI), and positron emission tomography (PET) scans. The market value includes the value of related goods sold by the service provider or included within the service offering. The multiple myeloma market also includes sales of thalidomide, bortezomib, and daratumumab which are used in providing multiple myeloma services. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Multiple Myeloma Market Characteristics
3. Multiple Myeloma Market Supply Chain Analysis
4. Global Multiple Myeloma Market Trends and Strategies
5. Multiple Myeloma Market Analysis of End Use Industries
7. Global Multiple Myeloma Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Multiple Myeloma Total Addressable Market (TAM) Analysis for the Market
9. Multiple Myeloma Market Segmentation
10. Multiple Myeloma Market Regional and Country Analysis
11. Asia-Pacific Multiple Myeloma Market
12. China Multiple Myeloma Market
13. India Multiple Myeloma Market
14. Japan Multiple Myeloma Market
15. Australia Multiple Myeloma Market
16. Indonesia Multiple Myeloma Market
17. South Korea Multiple Myeloma Market
18. Taiwan Multiple Myeloma Market
19. South East Asia Multiple Myeloma Market
20. Western Europe Multiple Myeloma Market
21. UK Multiple Myeloma Market
22. Germany Multiple Myeloma Market
23. France Multiple Myeloma Market
24. Italy Multiple Myeloma Market
25. Spain Multiple Myeloma Market
26. Eastern Europe Multiple Myeloma Market
27. Russia Multiple Myeloma Market
28. North America Multiple Myeloma Market
29. USA Multiple Myeloma Market
30. Canada Multiple Myeloma Market
31. South America Multiple Myeloma Market
32. Brazil Multiple Myeloma Market
33. Middle East Multiple Myeloma Market
34. Africa Multiple Myeloma Market
36. Multiple Myeloma Market Competitive Landscape and Company Profiles
37. Multiple Myeloma Market Other Major and Innovative Companies
40. Multiple Myeloma Market High Potential Countries, Segments and Strategies
41. Appendix
Executive Summary
Multiple Myeloma Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses multiple myeloma market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for multiple myeloma? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The multiple myeloma market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Treatment: Medications; Radiation Therapy; Stem Cell Transplant; Other Treatments2) By Diagnosis: Blood Tests; Bone Marrow Biopsy; Urine Tests; Imaging Tests
3) By Disease Type: Active Multiple Myeloma; Smoldering Multiple Myeloma
4) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy; Other Distribution Channels
Subsegments:
1) By Medications: Immunomodulatory Drugs (IMiDs); Proteasome Inhibitors; Monoclonal Antibodies; Corticosteroids; Chemotherapy Agents2) By Radiation Therapy: External Beam Radiation Therapy (EBRT); Radioisotope Therapy
3) By Stem Cell Transplant: Autologous Stem Cell Transplant (ASCT); Allogeneic Stem Cell Transplant
4) By Other Treatments: Supportive Care; Clinical Trials And Experimental Therapies
Companies Mentioned: Pfizer Inc.; Johnson & Johnson Private Limited; F. Hoffmann-La Roche Ltd.; Merck & Co. Inc.; AbbVie Inc.; Novartis AG; Sanofi S.A.; Bristol-Myers Squibb Company; AstraZeneca plc; GlaxoSmithKline PLC; Takeda Pharmaceutical Company Limited; Eli Lilly and Company; Amgen Inc.; Janssen Global Services LLC; Celgene Corporation; Biogen Inc.; Cipla Inc.; Sun Pharmaceutical Industries Ltd.; Karyopharm Therapeutics Inc.; Regeneron Pharmaceuticals Inc.; Gilead Sciences Inc.; Xencor Inc.; Oncopeptides AB; BeiGene Ltd.; TG Therapeutics Inc.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Multiple Myeloma market report include:- Pfizer Inc.
- Johnson & Johnson Private Limited
- F. Hoffmann-La Roche Ltd.
- Merck & Co. Inc.
- AbbVie Inc.
- Novartis AG
- Sanofi S.A.
- Bristol-Myers Squibb Company
- AstraZeneca plc
- GlaxoSmithKline PLC
- Takeda Pharmaceutical Company Limited
- Eli Lilly and Company
- Amgen Inc.
- Janssen Global Services LLC
- Celgene Corporation
- Biogen Inc.
- Cipla Inc.
- Sun Pharmaceutical Industries Ltd.
- Karyopharm Therapeutics Inc.
- Regeneron Pharmaceuticals Inc.
- Gilead Sciences Inc.
- Xencor Inc.
- Oncopeptides AB
- BeiGene Ltd.
- TG Therapeutics Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 30.25 Billion |
| Forecasted Market Value ( USD | $ 41.39 Billion |
| Compound Annual Growth Rate | 8.2% |
| Regions Covered | Global |
| No. of Companies Mentioned | 26 |
